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It is recognized that South Asians (defined as indi-viduals with ancestral origins in the Indian sub-
continent: India, Pakistan, Bangladesh, Nepal, and 
Sri Lanka) are at increased risk of coronary heart 
disease (CHD).1,2 Current data show that people of 
South Asian origin are 40% to 50% more likely to 
die from heart disease when compared with those 
of European origin.2,3 South Asians are generally 
The aim of this study was to determine the effects of ator-
vastatin in patients of South Asian versus European ori-
gin who participated in the Achieve Cholesterol Targets 
Fast with Atorvastatin Stratified Titration (ACTFAST) 
study. ACTFAST was a 12-week prospective, open-label 
study in patients at high risk for atherosclerosis (European 
origin, n = 1978; South Asian origin, n = 64). Compared 
with patients of European origin, patients of South Asian 
origin were younger, were less likely to smoke, and had 
lower body mass index, systolic blood pressure, low-den-
sity lipoprotein cholesterol (LDL-C) and triglycerides. 
Because significant differences were observed in baseline 
characteristics between patient groups, case control pro-
pensity scores were used. In the unmatched analysis, 
South Asians had greater LDL-C response to atorvastatin 
than patients of European origin. However, after propen-
sity matching, atorvastatin lowered LDL-C and high-sensi-
tivity C-reactive protein (hs-CRP) to a similar degree in 
both groups, with no differences in safety profile. The 
authors observed no correlation between change in hs-
CRP and LDL-C concentrations in either population. In 
conclusion, atorvastatin lowered both LDL-C and hs-CRP 
to a similar degree in patients of South Asian or European 
origin, suggesting usual starting doses of atorvastatin 
(with appropriate monitoring), rather than lower starting 
doses as has been advocated by some, may be used in 
patients of South Asian origin.
Keywords:  South Asians; ethnicity; coronary artery disease; 
statins; low-density lipoprotein cholesterol
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younger at the time of first myocardial infarction or 
development of heart failure, have larger myocardial 
infarctions, and have more severe coronary disease 
on angiography.4-6
An excess of conventional cardiovascular risk fac-
tors does not fully account for the excess risk of CHD 
observed in South Asians.4 Although diabetes has 
been shown to be more common in South Asians, 
other conventional risk factors such as smoking, 
hyperlipidemia, increased body mass index (BMI), 
hypertension, and previous vascular disease have 
generally been found to occur with similar or lower 
frequency among South Asians compared with con-
trol participants.1,4 Thus, it has been proposed that 
novel risk factors may play a dominant role in the devel-
opment of atherosclerosis in South Asians. 
Lipoprotein(a), apolipoprotein B (apo-B), homo-
cysteine, plasminogen activator inhibitor–1, fibrino-
gen, and C-reactive protein (CRP) have generated 
considerable interest. Blood concentrations of 
lipoprotein(a), homocysteine, and plasminogen 
activator inhibitor–1 tend to be higher in patients of 
South Asian compared with those of European ori-
gin.1 However, in current practice, South Asians are 
typically not screened for these emerging risk fac-
tors. Clinical trials have not enrolled sufficient 
numbers of South Asians to guide clinical practice, 
and consequently, diagnosis and treatment recom-
mendations are derived primarily from studies per-
formed in people of European origin.
Although dyslipidemia may not occur at a higher 
rate among South Asians, the type of dyslipidemia 
does seem to differ.1 People of South Asian origin 
have been found to have higher total cholesterol, 
low-density lipoprotein cholesterol (LDL-C), triglyc-
erides, and lipoprotein(a) and lower high-density 
lipoprotein (HDL-C) levels compared with popula-
tions of Chinese or European origin.1
Statin safety and efficacy data are mainly derived 
from populations of North American or European 
origin, which may not translate to similar results in 
patients of South Asian origin. For example, South 
Asians administered rosuvastatin have twice the 
drug concentration compared with patients of 
European origin treated with an equivalent dose,7,8 
leading to a recommendation that South Asians 
should be started on a lower dose of rosuvastatin or 
at least be more carefully monitored.
The Achieve Cholesterol Targets Fast with 
Atorvastatin Stratified Titration (ACTFAST) trial 
investigated whether selecting the starting dose of 
atorvastatin according to baseline and target LDL-C 
values would allow high-risk subjects to achieve 
target LDL-C concentrations rapidly, with either no 
titration or just 1 titration step, regardless of statin 
use at baseline. Atorvastatin reduces LDL-C levels 
by up to 60% and is well tolerated up to its maxi-
mum dose of 80 mg.9 In addition, it has been shown 
to slow the progression of atherosclerosis10 and reduce 
the incidence of cardiovascular events in both pri-
mary and secondary prevention of CHD.11-13
People of South Asian origin represent a large and 
growing population, and their underrepresentation 
in clinical trials is of concern. This article presents 
the results of a prespecified substudy of the ACTFAST 
trial performed to determine whether LDL-C and 
high-sensitivity CRP (hs-CRP) response to atorvasta-
tin is altered in high-risk patients of South Asian 
compared with those of European origin.
METHODS
Patient Population
The study design of ACTFAST has been described in 
detail elsewhere14 and is summarized below (Figure 1). 
ACTFAST was a 12-week, multicenter, prospective, 
open-label trial assessing the effectiveness of using 
starting doses of atorvastatin selected based on base-
line LDL-C and on the required LDL-C reduction to 
reach the target. High-risk patients aged 18 years and 
older were eligible for inclusion if they had dyslipi-
demia, defined as LDL-C >2.6 mmol/L (100 mg/dL) 
and ≤5.7 mmol/L (220 mg/dL) at screening, triglyc-
erides ≤6.8 mmol/L (600 mg/dL), and a history of 
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2.6-3.8 mmol/L = Atorvastatin 10mg
Titrate to 20mg
3.9-4.1mmol/L = Atorvastatin 20mg
Titrate to 40mg
4.2-4.4mmol/L = Atorvastatin 40mg
Titrate to 80mg
4.5-5.7mmo/L = Atorvastatin 80mg
6 weeks 12 weeksWeek 0
Patients
with CHD or 
CHD-equivalent 
or at high risk for 
CHD 
-1 week
Screening
(baseline)
Patients were titrated to the next dose 
if LDL-C target was not reached.
Add NCEP step II diet or equivalentOpen-label
Baseline LDL-C Dose assigned/titration
Figure 1. Study design. To convert mmol/L to mg/dL, multiply by 38.65. CHD, coronary heart disease; LDL-C, low-density lipoprotein 
cholesterol; nCEP: national Cholesterol Education Program. Adapted from Martineau et al.14
CHD, a CHD equivalent (diabetes, cerebrovascular 
disease, or peripheral vascular disease), or an esti-
mated 10-year CHD risk >20% as per the Framingham 
tables.15 Patients could be either statin free or statin 
treated at baseline and had to be willing to follow 
the National Cholesterol Education Program (NCEP) 
III multifaceted lifestyle approach (or local equiva-
lent).15 Patient ethnicity was self-reported.
Patients were considered ineligible for the study if 
they were receiving therapy with any statin at a dose 
>40 mg/d*, atorvastatin, fibrates, niacin or resins 
that could not be discontinued a minimum of 2 
months prior to enrollment, or strong inhibitors of 
CYP3A4. Patients were also excluded if they suf-
fered from specific systemic diseases, including 
impaired hepatic (defined as aspartate aminotrans-
ferase [AST] or alanine aminotransferase [ALT] ≥2 
times the upper limit of normal) or renal function 
(creatinine ≥181 µmol/L), uncontrolled diabetes 
(A1c >10%), uncontrolled hypertension (>160/100 
mm Hg), uncontrolled primary hypothyroidism (thy-
roid stimulating hormone ≥1.5 times the upper limit 
of normal), evidence of gastrointestinal disease limit-
ing drug absorption or partial ileal bypass, elevation 
of creatine kinase (CK) level (>3 times the upper limit 
of normal), alcohol and/or any other drug abuse, his-
tory of intolerance or hypersensitivity to statins, any 
severe disease or surgical procedure within 3 months 
prior to screening, or were women of childbearing 
potential not using appropriate contraception.
Treatment
Patients were assigned to 6 weeks of open-label 
treatment with atorvastatin according to their base-
line LDL-C level and prior statin use, followed by an 
additional 6-week open-label treatment during 
which patients who had not reached target LDL-C 
levels were titrated to the next highest dose of ator-
vastatin. Patients who were statin free with a base-
line LDL-C of 100 to 149 mg/dL (2.6-3.8 mmol/L), 
150 to 159 (3.9-4.1 mmol/L), 160 to 169 (4.2-4.4 
mmol/L), and 170 to 220 mg/dL (4.5-5.7 mmol/L) 
were assigned to 10, 20, 40 and 80 mg of atorvasta-
tin, respectively. Patients on a statin at baseline but 
*Rosuvastatin became commercially available in Canada and 
the United Kingdom during the trial, and the Steering Committee 
allowed patients on 10 mg to be enrolled in the study.
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whose LDL-C remained above target values received 
double the atorvastatin dose for the same baseline 
LDL-C level as compared with their untreated coun-
terparts, without any washout period. Patients with 
LDL-C 4.5 to 5.7 mmol/L (170–220 mg/dL) all received 
the 80-mg dose, regardless of statin use at baseline. 
Patients initially allocated to atorvastatin 80 mg who 
did not reach LDL-C targets remained on that dose, 
and a more intense therapeutic lifestyle intervention 
was recommended.
Blood samples were obtained at screening, week 6, 
and week 12 for the measurement of 12-hour fasting 
serum lipid profiles and routine safety blood meas-
urements. Patients received dietary counseling at all 
visits. The relevant institutional review boards 
approved the protocol, and informed consent was 
obtained from all patients. This study was con-
ducted in compliance with the ethical principles of 
the Declaration of Helsinki.16
Efficacy Parameters
The primary efficacy outcome of the main study was 
the proportion of patients achieving NCEP III target 
LDL-C levels of <2.6 mmol/L (<100 mg/dL) after 
12 weeks of treatment (termed LDL-C responders), 
using the last observation carried forward technique.14 
The objective of the current substudy was to com-
pare the degree of LDL-C and hs-CRP lowering between 
patients of South Asian and European origin.
Lipid Assays
Direct measurement of LDL-C was performed using a 
homogeneous enzymatic colorimetric assay (LDL-C 
Plus 2nd generation; Roche Diagnostics GmbH, 
Mannheim, Germany) by a central laboratory accred-
ited for lipid assays by the Centers for Disease Control 
and Prevention (CDC)/National Heart, Lung, and Blood 
Institute (NHLBI). This assay is reliable with triglycer-
ide plasma values up to 1200 mg/dL (13.5 mmol/L). 
Serum hs-CRP was assessed using a high-sensitivity, 
latex microparticle-enhanced immunoturbidimetric 
assay (Tina-Quant; Roche Diagnostics GmbH).
Statistical Analysis
Because of significant imbalances in baseline charac-
teristics between patients of South Asian and 
European origin, a 1:1 ethnicity match on propensity 
scores was used to reduce imbalance. A multivari-
ate logistic regression model was used to estimate 
propensity scores of being of South Asian origin. 
Covariates included in the logistic regression model 
were age, gender, baseline LDL-C, triglyceride and 
apo-B concentrations, baseline hs-CRP concentra-
tion, diastolic blood pressure (BP), systolic BP, smok-
ing status, diabetes, and history of CHD. Body mass 
index (BMI) was not included as a covariate because 
we wanted to compare South Asians and Europeans 
who had a comparable cardiometabolic risk profile. 
In addition, it is well known that for a given BMI/
waist circumference, South Asians have a greater 
percentage of body fat and a different pattern of body 
fat distribution than Europeans.17 Therefore, the BMI 
would not be the appropriate anthropometric varia-
ble to correct for differences in body fat/fat distribu-
tion between the 2 ethnic groups. We then matched 
each patient of South Asian origin to one of European 
origin with very similar propensity scores using 
Greedy matching techniques18 where the South Asian 
participants are ordered and sequentially matched to 
the nearest unmatched European origin. If more than 
1 unmatched is found, the matched European origin 
is selected at random. Statistical analysis was per-
formed using SAS software (SAS, Release 8.2; SAS 
Institute, Cary, North Carolina). P values <.05 were 
considered statistically significant. Categorical vari-
ables were analyzed using chi-square or Fisher exact 
test, where appropriate. Continuous variables were 
examined by t test for baseline characteristics and 
analysis of covariance (ANCOVA) adjusted for base-
line values for change from baseline to week 12. 
Because of the skewed distribution of serum hs-CRP 
levels, log-transformed values were used in the anal-
yses and back transformed for data presentation, 
yielding geometric means. Because of the large dif-
ference in group size and because unmatched groups 
may differ in various aspects, we only performed 
general safety comparisons.
RESuLTS
Study Population
The baseline demographics of patients enrolled in 
ACTFAST have been described previously.14 Briefly, 
the study recruited 2187 patients, including 64 of 
South Asian and 1978 of European origin. Participants 
were predominantly men of European origin with a 
mean age of 64 years. Every South Asian case could 
be matched with a case of European origin, except 
for 1 South Asian patient with an extremely high 
propensity score, thus yielding a total 63 patients in 
each group.
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Table I Baseline Characteristics of the Unmatched Population
Baseline Characteristics South Asian Origin (n = 64) European Origin (n = 1978) P Value
Age, y, mean ± SD 59 ± 12 64 ± 11 <.0001
Male, No. (%) 49 (77.0) 1330 (67.2) .12
BMI, kg/m2, mean ± SD 26.4 ± 3.6 29.2 ± 5.1 <.0001
LDL-C, mmol/L, mean ± SD 3.6 ± 0.5 3.8 ± 0.7 .003
Apo-B, g/L, mean ± SD 1.1 ± 0.2 1.1 ± 0.2 .12
Triglycerides, mmol/L, mean ± SD 2.2 ± 1.1 1.9 ± 0.9 .038
hs-CRP, mg/L
 Mean (raw data) 4.0 ± 4.5 5.2 ± 9.5 .28
 Geometric mean ± SD 2.5 ± 2.7 2.9 ± 2.8
Smoking status, No. (%)
 Never smoked 43 (67.0) 597 (30.2) <.0001
 Smoker 4 (6.0) 438 (22.1)
 Ex-smoker 17 (27.0) 943 (47.7)
Blood pressure, mm Hg, mean ± SD
 Systolic 130 ± 16 136 ± 17 <.007
 Diastolic 78 ± 11 79 ± 10 .48
Diabetes, No. (%) 32 (50.0) 752 (38.0) .052
History of CHD, No. (%) 46 (72.0) 1212 (61.3) .086
Apo-B, apolipoprotein B; BMI, body mass index; CHD, coronary heart disease; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density 
lipoprotein cholesterol.
Baseline Characteristics
The distributions of baseline covariates between 
patients of South Asian and European origin are 
displayed in Table I. Significant differences were 
observed in age, BMI, LDL-C, smoking status, systo-
lic BP, and triglycerides. No differences were observed 
between the 2 groups for gender, hs-CRP, diasto-
lic BP, history of CHD or diabetes, or apo-B concen-
trations.
After matching, no statistical differences were 
found for all observed covariates used in the logistic 
regression model, suggesting improvement in cov-
ariate balance between patients of South Asian and 
European origin, leading to comparable groups with 
regard to key baseline metabolic parameters and 
demographics (Table II).
LDL-C Response
In the unmatched population, the percentage reduc-
tion in LDL-C from baseline was significantly greater 
in patients of South Asian compared with European 
origin (P = .01; Figure 2). However, in the matched 
population, no significant difference was observed 
between the groups (P = .22). The proportion of LDL-C 
responders (LDL-C <2.6 mmol/L [<100 mg/dL]) after 
12 weeks of treatment trended in favor of a higher 
response rate in patients of South Asian origin (P = 
.05), but the difference remained nonsignificant in 
the matched populations (Figure 3).
Hs-CRP Response
The percentage change in hs-CRP was not signifi-
cantly different between patients of South Asian and 
European origin, in either the unmatched or matched 
groups (Figure 4).
Correlation Between LDL-C 
and Log (hs-CRP) Response
There were no correlations between baseline values 
of LDL-C and hs-CRP or change from baseline after 
12 weeks of treatment in the unmatched or matched 
populations (Table III). The only exception was a 
statistically significant, but clinically irrelevant, cor-
relation between change in LDL-C and hs-CRP (r2 = 
0.0024, P = .03) among patients of European origin, 
only observed in the unmatched population.
Safety
There was no difference in treatment-related or all-
causality adverse events in patients of South Asian 
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Table II Baseline Characteristics of the Matched Case Control Population
Baseline Characteristics
South Asian Origin Cases 
(n = 63)
Matched European Origin 
Cases (n = 63) P Value
Age, y, mean ± SD 59 ± 12 59 ± 11 .7
Male, No. (%) 48 (76.0) 49 (77.8) .83
BMI, kg/m2, mean ± SD 26.5 ± 3.6 29.5 ± 5.3 .0003
LDL-C, mmol/L, mean ± SD 3.6 ± 0.5 3.5 ± 0.5 .43
Apo-B, g/L, mean ± SD 1.1 ± 0.2 1.1 ± 0.2 .94
Triglycerides, mmol/L, mean ± SD 2.2 ± 1.1 2.3 ± 1.3 .4
hs-CRP, mg/L
 Mean (raw data) 4.0 ± 4.6 3.9 ± 5.1 .32
 Geometric mean ± SD 2.5 ± 2.7 2.1 ± 3.1
Smoking status, No. (%)
 Never smoked 43 (68.0) 41 (65.1) .8
 Smoker 4 (6.0) 3 (4.8)
 Ex-smoker 16 (25.0) 19 (30.2)
Blood pressure, mm Hg, mean ± SD
 Systolic 130 ± 16 131 ± 17 .75
 Diastolic 78 ± 11 79 ± 9 .78
Diabetes, No. (%) 32 (51.0) 32 (50.8) 1.0
History of CHD, No. (%) 45 (71.0) 45 (71.4) 1.0
Apo-B, apolipoprotein B; BMI, body mass index; CHD, coronary heart disease; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density 
lipoprotein cholesterol.
or European origin. Overall, the incidence of adverse 
events in South Asians was either lower than or 
similar to patients of European origin (Table IV).
DISCuSSIOn
Compared with patients of European origin, those of 
South Asian origin enrolled in ACTFAST were 
younger and leaner, smoked less, and exhibited 
lower systolic BP and LDL-C but had higher triglyc-
eride levels, despite lower BMI values. This difference 
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Table IV Safety
Safety Parameters, no. (%)
unmatched European 
Origin (n = 1978)
Matched European 
Origin (n = 63)
South Asian 
Origin (n = 63)
All-causality AEs 744 (37.6) 16 (25.0) 16 (25.0)
 Serious AEs 48 (2.4) 1 (1.6) 0
 Discontinuation of study drug because of AEs 84 (4.2) 0 0
  Dose reduction or temporary discontinuation 
 because of Aes
61 (3.1) 0 1 (1.6)
Treatment-related AEs 233 (11.8) 1 (2.0) 3 (5.0)
 Serious AEs 0 0 0
 Discontinuation of study drug because of AEs 65 (3.3) 0 0
  Dose reduction or temporary discontinuation 
 because of Aes
19 (1.0) 0 0
AE, adverse event.
Table III Correlation Between LDL-C and Log (hs-CRP) (LOCF)
unmatched Population Matched Case Control Population
Baseline EO: r2 = 0.00052; P = .31 EO: r2 = 0.010; P = .43
SAO: r2 = 0.0075; P = .50 SAO: r2 = 0.0055; P = .56
Change from baseline to week 12 EO: r2 = 0.0024; P = .03 EO: r2 = 0.012; P = .39
SAO: r2 = 0.024; P = .22 SAO: r2= = 0.025; P = .22
EO, European origin; hs-CRP, high-sensitivity C-reactive protein; LOCF, last observation carried forward; SAO, South Asian origin.
in risk factor profile between patients of South 
Asian and European origin has been noted in prior 
studies.1,4 Given the same lipid profile, South Asians 
had a lower BMI, which was expected based on 
previously published studies.17 This finding is con-
sistent with the observation that South Asians have 
a greater body fat content and more abdominal fat 
for a given BMI. After controlling for baseline differ-
ences, atorvastatin lowered LDL-C and hs-CRP to a 
similar degree in both groups.
LDL-C lowering with statin drugs has been 
shown to reduce the incidence of cardiovascular 
events in both primary and secondary prevention of 
CHD.11-13,19,20 However, few patients of South Asian 
origin have been enrolled in landmark clinical trials, 
making it difficult to determine if their response to 
statin therapy in terms of LDL-C lowering and car-
diovascular events are equivalent to those reported 
in populations of European origin.
Asians have historically been considered to be 
more responsive to the lipid-lowering effects of stat-
ins when compared with European populations.21-23 
Ethnic differences in response to statin therapy may 
be related to differences in pharmacokinetic and 
pharmacodynamic effects or to potential polymor-
phisms of genes involved in drug actions or the 
disease pathways.24 Although the data on increased 
response to statin therapy stem primarily from stud-
ies conducted in people of East Asian origin, par-
ticularly Japanese patients, this has led to the 
recommendation for lower statin initiation doses in 
all Asian patients.25 However, whether these recom-
mendations should also apply to South Asians, a 
population at high risk for CHD, remains unclear.
An analysis of data from the PRACTICE 
(Prospective Assessment of Cardiovascular risk 
and Treatment In Canadians of varying Ethnicity) 
registry, including 223 patients with CHD, found 
that atorvastatin and simvastatin, at commonly 
prescribed doses, modulate LDL-C and HDL-C lev-
els to a similar degree in patients of South Asian 
(n = 96) or European origin (n = 137).26 Atorvastatin 
(median 20 mg/d) produced similar decreases in 
LDL-C in patients of South Asian (43%) or European 
origin (41%), as did simvastatin (median 20 mg/d), 
35% and 37%, respectively. These results are simi-
lar to those found in ACTFAST, where reductions 
in LDL-C across all atorvastatin dosage groups 
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combined were not significantly different in patients 
of South Asian or European origin (38% and 34%, 
respectively, in the matched case control analysis). 
These findings suggest that statin dose adjustment 
may not be warranted in patients of South Asian 
origin.
Pharmacokinetic studies have shown a 2-fold 
elevation in rosuvastatin plasma concentration in 
patients of Asian compared to European origin, and 
the US Food and Drug Administration (FDA) has rec-
ommended the initiation of rosuvastatin at 5 mg/d in 
Asian patients.7,8 In the IRIS study (Investigation of 
Rosuvastatin In South Asian Subjects), exclusively 
conducted in South Asian patients in North America, 
usual rosuvastatin and atorvastatin dose ranges (10-
20 mg) allowed most patients to reach recommended 
LDL-C goals.27 However, this trial did not compare 
response to therapy in South Asian patients versus 
that of other ethnic groups. Because of differences in 
group size and characteristics between the 2 groups 
in ACTFAST, we only performed high-level com-
parisons of the safety of atorvastatin. No safety sig-
nal was apparent in patients of South Asian origin as 
compared those of European origin. Thus, atorvasta-
tin appears to be at least as safe in South Asians as 
it is in patients of European origin.
Hs-CRP has been proposed as an independent car-
diovascular risk factor that adds prognostic informa-
tion to that of conventional risk factors/Framingham 
risk score.28 A recent study reported that reducing 
hs-CRP with a statin in asymptomatic patients with 
LDL-C below the recommended threshold for ther-
apy led to reduction of cardiovascular events29; how-
ever, one cannot conclude that the benefit was a 
result of hs-CRP reduction. Also, there were very 
few South Asians in this study. We observed no dif-
ference in hs-CRP reduction in response to atorvas-
tatin between South Asians and those of European 
origin. Consequently, should hs-CRP reduction 
become a target for statin therapy in the future, clini-
cians do not need to reduce the dose of atorvastatin 
in South Asians.
Although this ACTFAST ethnicity substudy was 
prespecified, certain limitations must be considered: 
the study design was open-label and nonrand-
omized, leading to dose groups of unequal size; this 
small subgroup of South Asians may not be repre-
sentative of the overall South Asian population; the 
propensity score matching may not account for all 
potential differences (ie, those unmeasured) between 
patients of South Asian or European origin; and only 
one hs-CRP measurement was performed at each 
time point when the mean of 2 samples taken 2 weeks 
apart would have been optimal to account for vari-
ability in the measurement.30
COnCLuSIOn
These results suggest that the efficacy of atorvastatin 
in decreasing LDL-C and hs-CRP in patients of South 
Asian origin is similar to that seen in patients of 
European origin. The results of this and other stud-
ies indicate that lower initiation doses of atorvasta-
tin may not be required in patients of South Asian 
origin. Considering the high CHD risk in South 
Asian patients, identification and aggressive man-
agement of traditional and emerging CHD risk fac-
tors, particularly elevated LDL-C, are a priority.
The authors are grateful to the patients, investigators, and 
study coordinators without whom this study would not have 
been possible. The authors also thank Pauline Lavigne, from 
CMED, for her editorial assistance with the manuscript and 
Joseph Zoccoli, global clinical study manager from Pfizer 
Canada, for his invaluable contribution to the execution of this 
study.
Financial disclosure: This study was funded by Pfizer 
Canada. Dr Gupta has no financial disclosures. Dr Martineau and 
Thang Tran are employees of Pfizer Canada. Dr Després has 
received research funding from Eli Lilly Canada; has served on 
the speakers bureaus of Abbott Laboratories, AstraZeneca, Solvay 
Pharma, GlaxoSmithKline, and Pfizer Canada; and has been an 
advisory board member for Novartis, Theratechnologies, Torrent 
Pharmaceuticals Ltd, and sanofi-aventis. Dr Gaw has served as a 
consultant to Merck Sharp & Dohme, AstraZeneca International, 
Schering-Plough, and Bristol-Myers Squibb and is on the speakers 
bureaus for these companies. Dr de Teresa has no financial disclo-
sures. Dr Farsang has served as a consultant to sanofi-aventis, 
Pfizer, Servier, Egis Rt., and Richter, G.Rt. and is on the speakers 
bureau of sanofi-aventis. Dr Gensini has served as a consultant to 
Pfizer. Dr Leiter has received grants/research support from 
AstraZeneca International, Merck & Co, Merck/Schering-Plough 
Pharmaceuticals, and Pfizer and has also served as a consultant to 
these companies and on their speakers bureaus. Dr Blanco-Colio 
has no financial disclosures. Dr Egido has no financial disclosures. 
Dr Langer has received grants/research support from AstraZeneca 
International, Biovail Corporation, DuPont, Eli Lilly and Company, 
Fournier, GlaxoSmithKline, Guidant, Merck/Schering-Plough 
Pharmaceuticals, Novartis, Oryx Pharmaceuticals, Pfizer, Roche, 
sanofi-aventis, and Servier and is also a consultant to Merck/
Schering-Plough Pharmaceuticals, Novartis, Pfizer, Roche, and 
sanofi-aventis.
www.clinicaltrials.gov identification number: NCT00442845
REFEREnCES
1. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, 
atherosclerosis, and cardiovascular disease between ethnic groups 
in Canada: the Study of Health Assessment and Risk in Ethnic 
 at UNIV STUDI DI FIRENZE on December 28, 2011jcp.sagepub.comDownloaded from 
AToRvASTATIn In SouTH ASIAn AnD EuRoPEAn PATIEnTS
 9
groups (SHARE). Lancet. 2000;356:279-284.
2. Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Cardiovascular 
and cancer mortality among Canadians of European, South Asian 
and Chinese origin from 1979 to 1993: an analysis of 1.2 million 
deaths. CMAJ. 1999;161:132-138.
3. Wild S, McKeigue P. Cross sectional analysis of mortality by coun-
try of birth in England and Wales, 1970-92. BMJ. 1997;314:705-710.
4. Gupta M, Doobay AV, Singh N, et al. Risk factors, hospital man-
agement and outcomes after acute myocardial infarction in South 
Asian Canadians and matched control subjects. CMAJ. 2002; 
166:717-722.
5. Singh N, Gupta M. Clinical characteristics of South Asian 
patients hospitalized with heart failure. Ethn Dis. 2005;15:615-619.
6. Gupta M, Brister S. Is South Asian ethnicity an independent 
cardiovascular risk factor? Can J Cardiol. 2006;22:193-197.
7. Kim K, Birmingham B, Azumaya C, et al. Increased systemic 
exposure to rosuvastatin in Asian subjects residing in the United 
States compared with Caucasian subjects. Presented at: Annual 
Meeting of the American Society for Clinical Pharmacology and 
Therapeutics; April 2-5, 2008; Orlando, FL.
8. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacoki-
netics and pharmacogenetics in white and Asian subjects residing 
in the same environment. Clin Pharmacol Ther. 2005;78:330-341.
9. Lipitor (atorvastatin calcium) [prescribing information]. 
New York: Pfizer, Inc; 2009.
10. Nissen S, Tuzcu E, Schoenhagen P, et al. Effect of intensive 
compared with moderate lipid-lowering therapy on progression 
of coronary atherosclerosis: a randomized controlled trial. JAMA. 
2004;291:1071-1080.
11. Sever P, Dahlof B, Poulter N, et al. Prevention of coronary and 
stroke events with atorvastatin in hypertensive patients who have 
average or lower-than-average cholesterol concentrations, in the 
Anglo-Scandinavian Cardiac Outcomes Trial–Lipid lowering Arm 
(ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 
2003;361:1149-1158.
12. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. 
Safety and efficacy of atorvastatin-induced very low-density lipo-
protein cholesterol levels in patients with coronary heart disease 
(a post hoc analysis of the treating to new targets [TNT] study). 
Am J Cardiol. 2007;100:747-752.
13. Cannon C, Braunwald E, McCabe C, et al. Comparison of 
intensive and moderate lipid lowering with statins after acute 
coronary syndromes. n Engl J Med. 2004;350:1495-1504.
14. Martineau P, Gaw A, de Teresa E, et al. Effect of individual-
izing starting doses of a statin according to baseline LDL-
cholesterol levels on achieving cholesterol targets: the Achieve 
Cholesterol Targets Fast with Atorvastatin Stratified Titration 
(ACTFAST) study. Atherosclerosis. 2007;191:135-146.
15. National Cholesterol Education Program (NCEP). Executive 
summary of the Third Report of the National Cholesterol 
Education Program (NCEP) expert panel on detection, evaluation, 
and treatment of high blood cholesterol in adults (Adult Treatment 
Panel III). JAMA. 2001;285:2486-2497.
16. World Medical Association Declaration of Helsinki. Ethical 
principles for medical research involving human subjects. JAMA. 
2000;284:3043-3045.
17. Lear SA, Humphries KH, Kohli S, Birmingham CL. The use of 
BMI and waist circumference as surrogates of body fat differs by 
ethnicity. obesity (Silver Spring). 2007;15:2817-2824.
18. Parsons L. Reducing bias in a propensity score matched-pair 
sample using greedy matching techniques [paper 214-26]. 
Presented at: SUGI 26 Proceeding; April 22-25, 2001; Long 
Beach, CA.
19. Randomised trial of cholesterol lowering in 4444 patients 
with coronary heart disease: the Scandinavian Simvastatin Survival 
Study (4S). Lancet. 1994;344:1383-1389.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart 
Protection Study of cholesterol lowering with simvastatin in 
20,536 high-risk individuals: a randomised placebo-controlled 
trial. Lancet. 2002;360:7-22.
21. Matsuzawa Y, Kita T, Mabuchi H, et al. Sustained reduction of 
serum cholesterol in low-dose 6-year simvastatin treatment with 
minimum side effects in 51,321 Japanese hypercholesterolemic 
patients. Circ J. 2003;67:287-294.
22. Yamamoto A, Arakawa K, Sasaki J, et al. Clinical effects of 
rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese 
patients with primary hypercholesterolemia: an early phase II 
study. J Atheroscler Thromb. 2002;9:48-56.
23. Wu CC, Sy R, Tanphaichitr V, et al. Comparing the efficacy 
and safety of atorvastatin and simvastatin in Asians with elevated 
low-density lipoprotein-cholesterol: a multinational, multicenter, 
double-blind study. J Formos Med Assoc. 2002;101:478-487.
24. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 
2007;99:410-414.
25. McPherson R, Frohlich J, Fodor G, Genest J. Canadian 
Cardiovascular Society position statement: recommendations for 
the diagnosis and treatment of dyslipidemia and prevention of 
cardiovascular disease. Can J Cardiol. 2006;22:913-927.
26. Gupta M, Braga MF, Teoh H, Tsigoulis M, Verma S. Statin 
effects on LDL and HDL cholesterol in South Asian and white 
populations. J Clin Pharmacol. 2009;49:831-837.
27. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A. Comparison 
of rosuvastatin versus atorvastatin in South-Asian patients at risk 
of coronary heart disease (from the IRIS Trial). Am J Cardiol. 
2007;99:1538-1543.
28. Ridker P, Rifai N, Rose L, Buring J, Cook N. Comparison of 
C-reactive protein and low-density lipoprotein cholesterol levels 
in the prediction of first cardiovascular events. n Engl J Med. 
2002;347:1557-1565.
29. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to 
prevent vascular events in men and women with elevated 
C-reactive protein. n Engl J Med. 2008;359:2195-2207.
30. Pearson TA, Mensah GA, Alexander RW, et al. Markers of 
inflammation and cardiovascular disease: application to clinical 
and public health practice: a statement for healthcare profession-
als from the Centers for Disease Control and Prevention and the 
American Heart Association. Circulation. 2003;107:499-511.
For reprints and permission queries, please visit SAGE's Web site at http://www.sagepub.com/journalsPermissions.nav.
 at UNIV STUDI DI FIRENZE on December 28, 2011jcp.sagepub.comDownloaded from 
